Abstract #2921

MRI biomarkers for PEGPH20-enhanced treatment of pancreatic ductal adenocarcinoma

Ezekiel Maloney¹, Christopher DuFort², Ravneet Vohra¹, Markus Carlson², Navid Farr³, Paolo Provenzano⁴, Joshua Park¹, Sunil Hingorani², and Donghoon Lee¹

¹Radiology, University of Washington, Seattle, WA, United States, ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, ³Medical Devices Research, National Inststitute of Health, Bethesda, MD, ⁴Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN

Pancreatic cancer is a devastating disease with poor prognosis. Pancreatic tumor therapy has been ineffective in part because pancreatic tumors have high interstitial fluid pressure (IFP), driven by high hyaluronan concentration, that inhibits penetration of drugs into the tumor. We performed multi-parametric MRI at high resolution to non-invasively assess tumor response in a KPC mouse model to pegylated recombinant hyaluronidase in isolation as well as combined with Gemcitabine. T1 and T2 relaxation as well as diffusion, and 3 dimensional volume measurements were used to characterize the tumors. MR measurements were compared with invasive IFP measurements and histopathological results.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.